Condition: Hematological Malignancies · B-cell Non-Hodgkin Lymphoma · Sponsor: Daiichi Sankyo
This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
This description comes directly from the study's public registry record.
Daiichi Sankyo Contact for Clinical Trial Information · 908-992-6400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| Research Site | New York, New York, United States | Recruiting |
| Research Site | Lille, France | Recruiting |
| Research Site | Pierre-Bénite, France | Recruiting |
| Research Site | Nagoya, Japan | Recruiting |
| Research Site | Tokyo, Japan | Recruiting |
| Research Site | Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07220616